Peptonic Medical AB (publ) ("Peptonic" or the "Company") today publishes its Annual Report and Consolidated Financial Statements, together with the Auditor's Report, for the 2025 financial year. The Annual Report and the Auditor's Report are attached to this press release and are also available on the Company's website. The Company wishes to draw attention to the sections "Material uncertainty related to going concern" and "Remarks" in the Auditor's Report, which forms part of the 2025 Annual Report.
From the Auditor's Report:
Material uncertainty related to going concern
We draw attention to the Directors' Report, which states that the Company has reported losses for several consecutive years. Under the heading "Going concern assumptions" and in Note 2, it is further stated that the Company applied for company reorganisation in March 2025, which was approved and formally concluded in December 2025. The reorganisation enabled the Company to continue its operations with a lower level of debt than when the process began. Despite this, the Company continues to face strained liquidity, and there is a risk that it will not be able to generate sufficient funds to finance its operations. There is also a risk that the Company will not be able to obtain the necessary financing when required. These conditions indicate the existence of material uncertainties that may cast significant doubt on the Company's ability to continue as a going concern. Our opinions have not been modified in respect of this matter.
Remarks
On several occasions, the Company has failed to pay taxes and statutory charges on time.
The Annual Report is available on the Company's website: https://www.peptonicmedical.se/finansiell-information/
For further information, please contact:
Daniel Rudeklint, Interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Telephone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women's intimate health. Through the VagiVital and Vernivia brands, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common intimate health conditions. Peptonic's growth strategy is based on geographical expansion, particularly in the United States and Europe, and on continuously strengthening its product portfolio through in-house development and strategic acquisitions.